BioSenic S.A. (FRA:BT1)

Market Cap	1.57M -19.8%
Revenue (ttm)	-2.39M -69.6%
Net Income	-4.00M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3,946
Open	0.0021
Previous Close	0.0021
Day's Range	0.0021 - 0.0021
52-Week Range	0.0010 - 0.0040
Beta	n/a
RSI	49.04
Earnings Date	Apr 24, 2026

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium.

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Jean-Luc Vandebroek
• Employees: 7
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BT1

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.